-
Is it more and more difficult for Chinese patent medicine companies to increase the price of a large number of Chinese herbal medicines?
Time of Update: 2022-01-22
For the price increase of Chinese patent medicine, many pharmaceutical companies attribute the reason to the general price increase of traditional Chinese medicine raw materials due to factors such as climate and planting area, especially the scarcity of superimposed resources of precious and fine raw materials and the impact of contradiction between supply and demand .
-
The knockout stage of the pharmaceutical industry is accelerating, and innovation is the key to development
Time of Update: 2022-01-22
In order to seize new market development opportunities, companies need to continuously increase investment in innovative drug research and development or promote the development of generic drugs with core values .
-
Will the next price drop for centralized drug procurement be more than 50%?
Time of Update: 2022-01-22
Bidding is the process of making full use of the competition mechanism of the market, through which the bidder adopts a price reduction strategy to defeat the opponent in order to win the bid and achieve sales, so as to achieve the purpose of low-cost procurement .
-
Is the CXO sector still optimistic?
Time of Update: 2022-01-22
With the transfer of global pharmaceutical giants' R&D links to China, as well as the enthusiasm for new drug R&D, coupled with policy immunity, pharmaceutical research and production outsourcing services (CXO) can be said to be a sweet pastry in the pharmaceutical market .
-
Yunnan released the latest progress of the country's dual-channel drug talks
Time of Update: 2022-01-22
Designated medical institutions and "dual-channel" pharmacies implement unified payment standards and price policies for medical insurance drugs, that is, the national unified payment standard.
-
The State Food and Drug Administration revises the instructions for arbidol preparations
Time of Update: 2022-01-22
5. Provincial drug regulatory authorities shall urge the drug marketing authorization holders of the above-mentioned drugs within the administrative region to do a good job in revising the corresponding instructions and replacing the labels and instructions as required, and strictly investigate and punish violations of laws and regulations in accordance with the law .
-
The development of the pharmaceutical equipment industry continues to improve, and a large number of pharmaceutical machine companies will benefit
Time of Update: 2022-01-22
9%, and a net profit of 165 million yuan, a year-on-year increase of 413.
On the whole, the leading companies represented by Chutian and Tofflon performed very well last year, and their net profit increased significantly .
-
Guangdong Traditional Chinese Medicine pays according to the disease type, DIP, bed day, etc. All prefectural and municipal traditional Chinese medicine hospitals have reached the third level
Time of Update: 2022-01-22
The dividends of traditional Chinese medicine policies continue to be released. Guangdong clearly implements payment by disease for the dominant outpatient diseases of traditional Chinese medicine;
-
A large number of pharmaceutical companies have positive results, and the traditional Chinese medicine sector has performed well
Time of Update: 2022-01-22
According to the 2021 annual performance forecast released by Teyi Pharmaceutical on January 12, in 2021, Teyi Pharmaceutical is expected to have a net profit of 120 million yuan to 150 million yuan, a year-on-year increase of 173.
-
Inheritance and innovation of traditional Chinese medicine, we still need to do a good job of this
Time of Update: 2022-01-22
Industry insiders pointed out that focusing on "software and hardware" is conducive to promoting the innovation and development of traditional Chinese medicine.
" Of course, the software and hardware upgrades of traditional Chinese medicine enterprises It is also inseparable from the support of upstream equipment manufacturers in the industry chain.
-
The traditional Chinese medicine sector is differentiated, can the rising market continue?
Time of Update: 2022-01-22
Since the end of 2021, due to favorable policies, product price increases and other factors, the traditional Chinese medicine sector has continued to be hot and has attracted much attention from the capital market .
-
The latest news on the adjustment of the essential medicine list
Time of Update: 2022-01-22
Recently, the content of a communication meeting on the management measures of a list of essential medicines has spread in the industry. According to the WeChat public account Fengyun Yaotan, the mee
-
The release of heavy documents, the ophthalmic medical market may have major changes
Time of Update: 2022-01-21
In recent years, under the background of deepening aging, increasing work intensity, and changing life> . In this context, in order to further improve the people's eye health level and continue to pr
-
Drugs for rare diseases to treat "sausage mouth" are included in medical insurance, and rare diseases are accelerating to "not uncommon"
Time of Update: 2022-01-21
In order to solve the problem of expensive drugs for rare disease patients, since its establishment in 2018, the National Medical Security Administration has dynamically adjusted the medical insurance drug list once a year, and many rare disease drugs have also been included .
-
This week, another innovative drug company that has not yet made a profit will sprint for an IPO
Time of Update: 2022-01-21
Financial data shows that in 2018, 2019, 2020 and January-June 2021, Yifang Bio's net profit attributable to the company's shareholders was -103 million yuan, -94.
This time Yifang Bio chose to go public with the fifth set of listing standards on the Science and Technology Innovation Board .
-
Closing subsidiaries, laying off teams... A new round of "self-rescue" for pharmaceutical companies begins
Time of Update: 2022-01-21
The purpose of this adjustment to close the Plexxikon business is to maximize the concentration of resources on the development of 3 major ADC products .
-
Betta Pharma's PD-L1 Small Molecule Inhibitor for Solid Tumors or Lymphomas Obtained Clinical Approval
Time of Update: 2022-01-21
Betta Pharmaceutical PipelineFrom: Hong Kong stock prospectus in DecemberAccording to the Insight database, there are currently 5 oral PD-L1 small molecule drugs under development in China .
-
Keji Pharmaceuticals Appoints Richard John Daly as President of Its U.S. Company
Time of Update: 2022-01-21
Daly") was appointed as the president of its American company CARsgen Therapeutics Corporation, and Li Zonghai, founder, chairman of the board, CEO and chief scientific officer of Keji Pharmaceutical Dr.
-
2022 capital drama: Pfizer, Merck have shot!
Time of Update: 2022-01-21
In just two days on January 5th and January 6th, Pfizer and Merck made their moves one after another and reached capital cooperation with BioNTech and Exelead respectively, with a total amount of more than 1 billion US dollars, further consolidating and extending the industrial layout in the frontier field .
-
Renfu Medicine's Class 1.1 new drug Bairesi Pills was approved for clinical trials
Time of Update: 2022-01-21
According to the requirements of laws and regulations related to drug registration in China, Wuhan Renfu Innovative Drug Research and Development Center and Xinjiang Uygur Autonomous Region Uyghur Medical Research Institute will start the work related to clinical research of drugs after receiving the notice of drug clinical trial .
